Empyrean Taps China's Cancer Market with Disruptive Tech Partnership

BOCA RATON, Fla. – February 05, 2026 – U.S.-based Empyrean Medical Systems, Inc. has unveiled a landmark exclusive distribution agreement with Wide Code Industries Ltd., paving the way for its innovative cancer therapy technology to enter the vast Greater China market. The long-term partnership grants Wide Code the sole rights to market, sell, and support Empyrean's disruptive radiation oncology systems across Mainland China, Hong Kong, and Macau, marking a pivotal step in the American firm's global expansion strategy.

The deal represents a calculated, strategic entry into one of the world's largest and fastest-growing oncology sectors. While financial terms were not disclosed, the partnership model itself speaks volumes about the modern approach to penetrating complex international markets.

The Strategic Blueprint for a Complex Market

For Western medical technology companies, the allure of China's market is matched only by its complexity. Navigating its intricate regulatory landscape, vast geography, and unique business culture presents formidable challenges. Rather than undertaking the capital-intensive and high-risk endeavor of building a direct commercial infrastructure, Empyrean has opted for a strategic alliance.

This distributor-led joint venture model allows Empyrean to leverage the deep-rooted expertise of a local champion. Founded in 1990, Wide Code Industrial Group brings over three decades of experience, an extensive distribution network, and a proven track record of commercializing products for international medical brands in the region.

"Greater China is an important and strategic growth market for us, but it requires local scale and execution capability," said Kal Fishman, chief executive officer of Empyrean Medical Systems. "This agreement allows us to enter the region in a disciplined way while maintaining capital efficiency and operational focus."

This capital-light approach is crucial for a growth-stage company like Empyrean, allowing it to focus resources on research, development, and production. Wide Code will manage the on-the-ground responsibilities of sales, channel development, and market expansion, including plans for future localization of the products.

Jordan Sun, CEO of Wide Code, underscored the mutual confidence behind the deal. "We observe robust and sustained demand for advanced oncology treatment technologies across Greater China," Sun stated. "Empyrean's disruptive scientific approach and exceptional product platform align closely with the needs of local healthcare institutions to elevate treatment standards. This collaboration is not merely a commercial distribution agreement but a long-term strategic win-win partnership."

A New Weapon in the Fight Against Cancer

At the heart of this partnership is Empyrean's groundbreaking technology: Magnetically Optimized Very High Energy Electron Therapy (MOVHEET). Born from research at the prestigious MD Anderson Cancer Center, MOVHEET represents a potential paradigm shift in how radiation therapy is delivered.

Unlike conventional radiation, which uses x-ray photons, or traditional electron beams with limited penetration, MOVHEET utilizes very-high-energy electron (VHEE) beams guided by a sophisticated magnetic system. This allows the technology to achieve what was previously the domain of far more expensive and complex systems: treating deep-seated tumors with extraordinary precision.

The system is designed to focus the radiation dose directly within the tumor, significantly reducing the entry dose and minimizing the exit dose that can damage surrounding healthy tissue and organs. This enhanced precision could lead to more effective tumor destruction while reducing the debilitating side effects often associated with radiation treatment.

MOVHEET is positioned to disrupt a market currently dominated by two main technologies. On one end are conventional linear accelerators, which are widely available but have limitations in tissue sparing. On the other is proton therapy, which offers superior precision but comes with a prohibitive price tag and requires massive, complex facilities. Empyrean's technology aims to occupy a critical middle ground, offering proton-like benefits in a machine with a footprint and cost structure closer to that of a conventional system. Furthermore, the platform is being developed to support FLASH radiotherapy, an experimental ultra-high dose rate technique that could further revolutionize treatment efficacy and safety.

Tapping into Unprecedented Demand

The Empyrean-Wide Code partnership is timed to meet a critical and growing need. Greater China is facing a significant cancer burden, driven by demographic shifts, lifestyle changes, and a rapidly aging population. Lung, colorectal, stomach, and breast cancer rates are on the rise, placing immense pressure on the healthcare system.

In response, the Chinese government has made healthcare a national priority, with initiatives like the "Healthy China 2030" plan fueling massive investment in hospital infrastructure and advanced medical technology. This has created a fervent demand for more effective and accessible cancer treatments.

The current radiation oncology landscape is dominated by established global giants like Varian (a Siemens Healthineers company) and Elekta. Empyrean's entry with a novel technology, backed by a powerful local partner, is set to introduce a new competitive dynamic. By offering a solution that promises improved clinical outcomes with potentially favorable health economics, MOVHEET could appeal to a broad range of Chinese hospitals looking to upgrade their capabilities beyond standard photon therapy without committing to the astronomical cost of a proton center.

A Model for Global Expansion

Empyrean's leadership views the agreement as more than just a gateway to China; it is a foundational template for its entire international strategy. The company has explicitly stated its goal is to build a scalable global commercial platform through selective, long-term partnerships rather than direct expansion in every market.

"Our priority is establishing repeatable global growth," Fishman noted. "This partnership reflects how we intend to scale—by working with established regional operators and maintaining a focused balance sheet."

This model is particularly astute for navigating the complex regulatory pathways for high-risk medical devices. Gaining approval from China's National Medical Products Administration (NMPA) is a rigorous, time-consuming process. Wide Code's experience in this arena, coupled with its role in potential future localization efforts, will be invaluable in bringing Empyrean's technology to patients.

As Empyrean looks to replicate this success in other key international regions, the partnership with Wide Code will serve as a crucial case study. It demonstrates a nimble, strategic approach to global commerce, prioritizing collaboration and local expertise to deliver cutting-edge medical innovation to the parts of the world that need it most.